Publications by authors named "Gisbert Selke"

Claim this Profile
T
Trends in antipsychotic and antidepressant prescriptions among German adolescents: Data from the largest statutory health insurance in Germany.
Isabel Hach, Luana F Tanaka, Uwe Eichler, Irene Langner, Simon Jäger, Gisbert W Selke

Psychiatry Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.
Ivar Veszelei, Brian Godman, Katri Aaltonen, Gisbert W Selke, Kristina Garuolienė

BioDrugs· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 pandemic on antidepressant use in eleven European regions: a comparative time series analysis 2018-2022.
Iva Selke Krulichová, Adam Hallberg, Gisbert W Selke, Katri Aaltonen, Manuela Casula

Soc Psychiatry Psychiatr Epidemiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries.
Szczepan Jakubowski, Przemysław Holko, Rafał Nowak, Marisa Warmuth, Marc Dooms, Gisbert W Selke

Front Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribing of valproate and oral antiepileptics for women of childbearing age and during pregnancy in Germany between 2010 and 2020.
Katrin Scholz, Ingrid Köster, Ingo Meyer, Gisbert W Selke, Ingrid Schubert

Pharmacoepidemiol Drug Saf· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications".
Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Iva Selke Krulichová, Gisbert Selke

Biomed Res Int· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study.
Iva Selke Krulichová, Gisbert W Selke, Marion Bennie, Mohammadhossein Hajiebrahimi, Fredrik Nyberg

Pharmacoepidemiol Drug Saf· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Iva Selke Krulichová, Gisbert Selke

Biomed Res Int· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany.
Iva Selke Krulichová, Gisbert W Selke, Petra A Thürmann

Eur J Clin Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Brian Godman, Andrew Hill, Steven Simoens, Gisbert Selke, Iva Selke Krulichová

Expert Rev Pharmacoecon Outcomes Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Gisbert W Selke

Front Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative Review of Managed Entry Agreements: Chances and Limitations.
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Gisbert W Selke

Pharmacoeconomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G Vulto, Martin Schulz, Gabriele Gradl, Gisbert Selke

Pharmaceuticals (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, Merce Obach, Cristina Nadal, Gisbert Selke

Appl Health Econ Health Policy· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Patricia Vella Bonanno, Anna Bucsics, Steven Simoens, Antony P Martin, Wija Oortwijn, Gisbert Selke

Expert Rev Pharmacoecon Outcomes Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications.
Iva Selke Krulichová, Gisbert W Selke, Uwe Eichler, Veronika Lappe, Brian Godman

Curr Med Res Opin· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C Rothe, Gisbert Selke

Front Public Health· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Policies for biosimilar uptake in Europe: An overview.
Evelien Moorkens, Arnold G Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Gisbert W Selke

PLoS One· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Patricia Vella Bonanno, Michael Ermisch, Brian Godman, Antony P Martin, Jesper Van Den Bergh, Gisbert Selke

Front Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, Francis Arickx, Alexander Bybau, Gisbert Selke

Front Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe.
Wojciech Matusewicz, Brian Godman, Hanne Bak Pedersen, Jurij Fürst, Jolanta Gulbinovič, Gisbert Selke

Expert Rev Pharmacoecon Outcomes Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality indicators as a tool in improving the introduction of new medicines.
Stephen M Campbell, Brian Godman, Eduardo Diogene, Jurij Fürst, Lars L Gustafsson, Gisbert Selke

Basic Clin Pharmacol Toxicol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Brian Godman, Rickard E Malmström, Eduardo Diogene, Andy Gray, Sisira Jayathissa, Gisbert Selke

Expert Rev Clin Pharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Brian Godman, Rickard E Malmström, Eduardo Diogene, Sisira Jayathissa, Stuart McTaggart, Gisbert Selke

Front Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalizing health care: feasibility and future implications.
Brian Godman, Alexander E Finlayson, Parneet K Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Gisbert Selke

BMC Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis